

BGI SENTIS[™]


Cancer+ Discovery NGS Panel



INTRODUCTION

Technological advances combined with an improved understanding of the genetic basis of cancer has revolutionized the way we manage cancer. Utilizing the patient's particular genomic profile, clinicians can now assess the risk of hereditary cancer for the patient and the patient's family, also tailor the best treatment options.

BGI's SENTIS[™] Cancer+ Discovery NGS Panel provides your labs with one of the market's most comprehensive and accurate NGS-based testing solution for the identification of actionable somatic and germline mutations and the discovery of novel variants with important functions in cancer. The panel offers exon coverage of 688 cancer-related genes and interrogates the most common types of alterations, including SNVs, indels, CNVs and fusions in solid tumors.




MSI: Microsatellite Instability TMB: Tumor Mutation Burden

PANEL APPLICATIONS

1. Targeted Therapy

- » Covers 166 therapy target genes for interpretation of over 300 drugs.
- » Includes FDA and NCCN guideline-recommended companion diagnostic genes.
- 2. Immunotherapy Evaluation
 - » High-concordance TMB results (R²>0.95) with whole-exome sequencing.
 - » BGI's proprietary EDB-MSI algorithm for precise evaluation (95%+ sensitivity and specificity).
 - » Includes evaluation of 23 Immune positive and negative genes.
- 3. Hereditary Risk
 - » Covers 69 hereditary cancer genes for risk evaluation of breast, ovarian, colon cancer, and more.



BGI's early access program enables your end-to-end testing of various sample types with the following proven products/platforms (**RUO in the US and Canada**).





MGISP-100* Automated Sample Preparation System

DNBSEQ-G400* Sequencer

*The automation and sequencing instruments are supplied by Complete Genomics directly.



BGI Halos Health Analysis in One-Step



SENTIS[™] Cancer+ Discovery Panel Reagent Set

For Research Use Only. Not for use in diagnostic procedures.



www.bgi.com/us bgi-discover@bgi.com

Copyright© BGI 2023. All trademarks are the property of BGI or their respective owners. This material contains information on products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.